Cleveland Clinic appoints oncologist as chair of Taussig Cancer Institute
Click Here to Manage Email Alerts
Alex A. Adjei, MD, PhD, has been appointed chair of Cleveland Clinic Taussig Cancer Institute.
Adjei previously served as consultant in oncology, professor of oncology and professor of pharmacology at Mayo Clinic and Mayo Clinic College of Medicine and Science in Rochester, Minnesota.
While there, he co-led the developmental therapeutics program at Mayo Clinic Cancer Center. He also oversaw oncology drug development, as well as lung cancer research and treatment across multiple Mayo Clinic sites.
“It’s an honor to welcome Dr. Adjei to lead our Taussig Cancer Institute,” Beri Ridgeway, MD, chief of staff at Cleveland Clinic, said in a press release. “His clinical expertise, extensive research accomplishments in oncology, and significant leadership experience will benefit our institute and advance patient care.”
Adjei’s research has focused on experimental therapeutics, regulatory science and clinical drug development, as well as health disparities, global oncology, new drug treatments for lung cancer and the effects of drug toxicities.
“Cancer is one of the most distressing diseases afflicting humans,” Adjei said in the release. “Thankfully, with recent scientific advances, we are making progress toward understanding, preventing and treating all forms of cancers. I’m truly honored and excited to have the opportunity to work with this team of talented professionals and help position Cleveland Clinic at the forefront of cancer care.”
Adjei previously served as chair in cancer medicine, senior vice president of clinical research, chairman of the department of medicine and professor of oncology at Roswell Park Comprehensive Cancer Center.
Jame Abraham, MD — who had served as interim chair of Taussig Cancer Institute since May 2021 — will continue to serve as chair of the department of hematology and medical oncology at Taussig Cancer Institute.
Read more about
Click Here to Manage Email Alerts